Costas K. Yannakou, MD

Clinical Haematologist
Epworth Healthcare, Freemasons Hospital and University of Melbourne, Australia

N/A

Poster(s):

• 1206 - First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies